Skip to main
BIIB

Biogen (BIIB) Stock Forecast & Price Target

Biogen (BIIB) Analyst Ratings

Based on 20 analyst ratings
Buy
Strong Buy 35%
Buy 20%
Hold 40%
Sell 5%
Strong Sell 0%

Bulls say

Biogen is a well-established biopharmaceutical company with a strong track record of success in treating neurodegenerative and rare diseases. Its diverse revenue streams, including collaborations and newer franchises, provide a solid foundation for future growth and financial stability. The company has a promising pipeline with key catalysts approaching, and its commitment to sustainability and diversity is commendable. While there are some risks, including competition and potential setbacks, the company's strategic initiatives and strong financial performance make it an attractive long-term investment opportunity.

Bears say

Biogen is an established biopharmaceutical company that has been facing numerous challenges in recent years. The company's declining multiple sclerosis franchise, which is its largest revenue generator, has been facing increasing competition and pricing pressures. In addition, Biogen's newer franchises, including Spinraza and Leqembi, have not been able to fully offset the declining sales from its MS drugs. Furthermore, the company is heavily reliant on its collaboration agreements with Roche and other partners, which can be unpredictable and may not generate consistent revenue in the long term. This, combined with Biogen's high operating expenses and ongoing pipeline challenges, leads to a negative outlook for the company's stock.

Biogen (BIIB) has been analyzed by 20 analysts, with a consensus rating of Buy. 35% of analysts recommend a Strong Buy, 20% recommend Buy, 40% suggest Holding, 5% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Biogen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Biogen (BIIB) Forecast

Analysts have given Biogen (BIIB) a Buy based on their latest research and market trends.

According to 20 analysts, Biogen (BIIB) has a Buy consensus rating as of May 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $209.95, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $209.95, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Biogen (BIIB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.